Three-month safety data from a Phase I clinical trial in China for Cellular Biomedicine’s AlloJoin™ off-the-shelf allogeneic stem cell therapy in the treatment of knee osteoarthritis demonstrated a safety and tolerability profile of AlloJoin in the three doses tested, with adverse events similar to that of earlier autologous trials. The trial is slated for completion in 3Q17.
Summary of trial data:
No Serious Adverse Events observed for any patients
Most common Adverse Events are knee pain and swelling after injection, with severity similar to earlier autologous trials (mild to moderate)
Three-month safety data from a Phase I clinical trial in China for Cellular Biomedicine's AlloJoin™ off-the-shelf allogeneic stem cell therapy in the treatment of knee osteoarthritis demonstrated a safety and tolerability profile of AlloJoin in the three doses tested, with adverse events similar to that of earlier autologous trials. The trial is...
Three-month safety data from a Phase I clinical trial in China for Cellular Biomedicine’s AlloJoin™ off-the-shelf allogeneic stem cell therapy in the treatment of knee osteoarthritis demonstrated a safety and tolerability profile of AlloJoin in the three doses tested, with adverse events similar to that of earlier autologous trials. The trial is slated for completion in 3Q17.
Summary of trial data:
No Serious Adverse Events observed for any patients
Most common Adverse Events are knee pain and swelling after injection, with severity similar to earlier autologous trials (mild to moderate)
Copy to clipboard 
